Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Hikma Pharmaceuticals plc SWOT & PESTLE Analysis

ID : 521070753| Nov 2021| 18 pages

COMPANY PROFILE -Hikma Pharmaceuticals plc

Business Sector :Pharmaceuticals

Operating Geography :United Kingdom, Europe, Global

About Hikma Pharmaceuticals plc :

Hikma Pharmaceuticals plc is a non-branded generic and in-licensed pharmaceutical company headquartered in London, United Kingdom. In 1978, Samih Darwazah founded the company in Amman, Jordan. The company has 29 manufacturing facilities spread across 11 countries: the United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, Tunisia, and Sudan. It undertakes research and development in the areas such as cardiology, anti-infective, neurology, and dermatology. In the MENA region, Hikma's branded business segment consists of the development and sale of branded generics and in-licensed patented products. It offers 499 different medications in 1,256 different dosage strengths. Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax are some of the most popular products. Argatroban, fentanyl, phenylephrine, Robaxin, and iron gluconate are among the speciality injectable medications sold by Hikma in the United States, Europe, and MENA. Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC announced in August, 2021, that they have entered into a marketing and licence agreement in the United States for BAT2206, a monoclonal antibody that is a potential biosimilar referencing Stelara (US).

Hikma Pharmaceutical's USP lies in its reputation for quality, high brand awareness, and FDA-inspected manufacturing facilities in the United States. The mission statement of Hikma Pharmaceuticals reads, "Improving lives' is Hikma's main mission, through providing high-quality affordable medication to patients and 'Improving lives' of its local communities and its employees".

Hikma Pharmaceuticals plc Revenue :


US$ 2,341 million - FY ending 31st December 2020 (y-o-y growth 6%)
US$ 2,207 million - FY ending 31st December 2019

Competitive Analysis of Hikma Pharmaceuticals plc

SWOT
PESTLE
The SWOT analysis for Hikma Pharmaceuticals plc is presented below in a matrix followed by the detailed analysis report:
StrengthsWeaknesses
1. Strongly positioned to deliver sustainable growth
2. World-class infrastructure for generics development and manufacturing
3. Manufacturing flexibility can handle fluctuating demand
4. Continuous launch of new drugs
5. Leading supplier of nasal sprays in the United States
6. One of the largest pharmaceutical brands in MENA
7. Consistently maintained cash flow that supports R&D
1. Presence in few product categories
2. High dependence on conventional sales channels
OpportunitiesThreats
1. High demand for Covid-19 treatment drugs
2. Elective surgery products will see demand post covid
3. Biosimilar received a positive response in US
1. Patent infringement litigation with Amarin pharma
2. Emerging innovative sales channels increase competition
3. Reduced supply of APIs is inhibiting production
SWOT & PESTLE (combined)
Complete Report
USD 27
*
  • Debit/Credit card
  • PayPal
Great quality, Affordable pricing.
Safe and secure payments
This is a custom report and will be delivered to your email inbox within 2 business days from purchase.

Detailed SWOT Analysis of Hikma Pharmaceuticals plc

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

1. High demand for Covid-19 treatment drugs: Pharmaceuticals industry saw a tectonic shift in demand towards drugs used for treatment of Covid-19 induced symptoms. Drugs such as Hydroxychloroquine, Ivermectin and Favipiravir were in massive demand across the globe. The international trade of these drugs and their APIs became a global political issue. Recently Remdesivir injections were in high demand for the treatment. Other than these, many pain, respiratory, sedative, and anesthetic drugs are seeing an exponential rise in demand. The other drugs that are required in curing of miscellaneous infectious diseases experienced subdued demand, as there was low occurrence of such diseases in social distancing environment and through lockdown phases. This trend is envisaged to continue until Covid-19 gets completely eradicated. Hikma ramped up its production to meet the demand for Covid related drugs. It also started manufacturing of Remdesivir. Hikma will continue to see success in launch of Covid-19 related drugs.

The remaining section under "Opportunity" is available only in the 'Complete Report' on purchase.

Threat

1. Patent infringement litigation with Amarin pharma: Hikma Pharmaceuticals is involved in many litigations due to the nature of generics business. But it attracted negative spotlight in the recent scandal with Amarin Corporation Plc. This lawsuit has been filed in district court of Delaware, against Hikma’s US affiliate. Amarin states that the sale of icosapent ethyl capsules, in the USA, by Hikma Pharmaceuticals is violation of Amarin’s patent rights. The product is used in reduction of cardiovascular risks. So Amarin intends to stop further launch of similar products from other pharmaceutical companies and penalize Hikma. Amarin has an upper hand in this litigation as they already have an expertise in icosapent ethyl capsules with numerous patents across the globe. Hikma’s ‘branded’ vertical will find it difficult to secure licenses for manufacturing of drugs.

The remaining section under "Threat" is available only in the 'Complete Report' on purchase.

Major Competitors :

Major Brands :

  • Mitigare
  • ADRIAMYCIN
  • ALLOPURINOL
  • AMIKACIN
  • CISplatin
  • DURAMORPH
  • FLUMAZENIL
  • IDARUBICIN
  • Zortress
  • PROPOFOL
SWOT & PESTLE (combined)
Complete Report
USD 27
*
  • Debit/Credit card
  • PayPal
Great quality, Affordable pricing.
Safe and secure payments
This is a custom report and will be delivered to your email inbox within 2 business days from purchase.
TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?

You may also be interested in other analyses of Hikma Pharmaceuticals plc:

Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Company Overview Report
This report is shared in order to give you an idea of what the complete Company Overview Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Competitor Analysis Report
This report is shared in order to give you an idea of what the complete Competitor Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Porter's Five Forces Analysis Report
This report is shared in order to give you an idea of what the complete Porter's Five Forces Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
VRIO Analysis Report
This report is shared in order to give you an idea of what the complete VRIO Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Value Chain Analysis Report
This report is shared in order to give you an idea of what the complete Value Chain Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Regulatory Outlook Report
This report is shared in order to give you an idea of what the complete Regulatory Outlook Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Risk Analysis Report
This report is shared in order to give you an idea of what the complete Risk Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Key Performance Indicators (KPI's) Report
This report is shared in order to give you an idea of what the complete Key Performance Indicators (KPI's) Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Environmental, Social, and Governance (ESG) Analysis Report
This report is shared in order to give you an idea of what the complete Environmental, Social, and Governance (ESG) Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
M&A Analysis Report
This report is shared in order to give you an idea of what the complete M&A Report and Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Subsidiaries, Partnerships and Collaborations Report
This report is shared in order to give you an idea of what the complete Subsidiaries, Partnerships and Collaborations Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Stakeholder Analysis Report
This report is shared in order to give you an idea of what the complete Stakeholder Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Technology Landscape and Outlook Report
This report is shared in order to give you an idea of what the complete Technology Landscape and Outlook Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Covid-19 Impact Analysis Report
This report is shared in order to give you an idea of what the complete Covid-19 Impact Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Key News and Events Report
This report is shared in order to give you an idea of what the complete Key News and Events Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
BCG Analysis Report
This report is shared in order to give you an idea of what the complete BCG Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Digital Marketing and Social Media Strategy Analysis Report
This report is shared in order to give you an idea of what the complete Digital Marketing and Social Media Strategy Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Segmentation, Targeting and Positioning (STP) Analysis Report
This report is shared in order to give you an idea of what the complete Segmentation, Targeting and Positioning (STP) Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Request for Quotation
Hikma Pharmaceuticals plc
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.
Get The Free Sample
Ansoff Matrix Analysis Report
This report is shared in order to give you an idea of what the complete Ansoff Matrix Analysis Report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
We do not share your information with anyone. However, we may send you emails on our new reports and solutions.

Check Out Analysis of Other Relevant Companies

References used in Hikma Pharmaceuticals plc SWOT & PESTLE Analysis Report

1. Meet the Management Series – Generics September 2021 - https://www.hikma.com/media/3045/generics-mtm-presentation_v21-final.pdf

2. Hikma Pharmaceuticals PLC Annual Report 2020 - https://www.hikma.com/media/2916/2020-full-ar.pdf

3. Covid-19 Created an Elective Surgery Backlog. How Can Hospitals Get Back on Track? - https://hbr.org/2020/08/covid-19-created-an-elective-surgery-backlog-how-can-hospitals-get-back-on-track

4. Hikma Pharmaceuticals PLC (HKMPF) CEO Siggi Olafsson on Q4 2020 Results - Earnings Call Transcript | Seeking Alpha - https://seekingalpha.com/article/4409984-hikma-pharmaceuticals-plc-hkmpf-ceo-siggi-olafsson-on-q4-2020-results-earnings-call#:~:text=So%20this%20isn't%20just%20a%20Hikma%20problem

5. Sudan inflation soars, raising spectre of hyperinflation - https://www.reuters.com/article/us-sudan-economy-idUSKBN2890CH

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Hikma Pharmaceuticals plc SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2021). Hikma Pharmaceuticals plc SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/hikma-pharmaceuticals/ [Accessed 08 Dec, 2021].

In-text: (SWOT & PESTLE.com, 2021)

Copyrights and Disclaimer

Hikma Pharmaceuticals plc SWOT and PESTLE analysis has been conducted by Mohit Harishchandra Deshmukh and reviewed by senior analysts from Barakaat Consulting.

Copyright of Hikma Pharmaceuticals plc SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

Hikma Pharmaceuticals plc SWOT & PESTLE Analysis
Price : USD 27
Open chat
1
Hello
How can I Help You?